West Pharmaceutical Valuation
| WST Stock | USD 250.49 6.88 2.82% |
At this time, the company appears to be fairly valued. West Pharmaceutical maintains a prevalent Real Value of $253.58 per share. The last-minute price of the company is $250.49. Our model calculates the value of West Pharmaceutical from examining the company fundamentals such as Current Valuation of 17.58 B, profit margin of 0.16 %, and Return On Asset of 0.0968 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting West Pharmaceutical's valuation include:
Price Book 5.682 | Enterprise Value | Enterprise Value Ebitda 23.2394 | Price Sales 5.8704 | Forward PE 33.3333 |
Fairly Valued
Today
Please note that West Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of West Pharmaceutical is based on 3 months time horizon. Increasing West Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
West Pharmaceutical's intrinsic value may or may not be the same as its current market price of 250.49, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 250.49 | Real 253.58 | Target 319.29 | Hype 250.55 |
The intrinsic value of West Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence West Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of West Pharmaceutical Services helps investors to forecast how West stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of West Pharmaceutical more accurately as focusing exclusively on West Pharmaceutical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use West Pharmaceutical's intrinsic value based on its ongoing forecasts of West Pharmaceutical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against West Pharmaceutical's closest peers.
West Pharmaceutical Cash |
|
West Revenue by Product
West Pharmaceutical Total Value Analysis
West Pharmaceutical Services is at this time projected to have company total value of 17.58 B with market capitalization of 18.05 B, debt of 1.09 B, and cash on hands of 791.3 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the West Pharmaceutical fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.58 B | 18.05 B | 1.09 B | 791.3 M |
West Pharmaceutical Investor Information
About 98.0% of the company outstanding shares are owned by institutional investors. The company recorded earning per share (EPS) of 6.79. West Pharmaceutical last dividend was issued on the 28th of January 2026. The entity had 2:1 split on the 27th of September 2013. West Pharmaceutical Services is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.1 | 0.1903 |
|
| |||||
| Total Cash From Operating Activities | 792.5 M | 754.8 M |
|
| |||||
| Operating Income | 614.1 M | 584.9 M |
|
|
West Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. West Pharmaceutical has an asset utilization ratio of 71.99 percent. This implies that the Company is making $0.72 for each dollar of assets. An increasing asset utilization means that West Pharmaceutical Services is more efficient with each dollar of assets it utilizes for everyday operations.West Pharmaceutical Profitability Analysis
Taking into consideration West Pharmaceutical's profitability measurements, West Pharmaceutical's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess West Pharmaceutical's ability to earn profits and add value for shareholders.Net Income | First Reported 1985-09-30 | Previous Quarter 140 M | Current Value 132.1 M | Quarterly Volatility 46.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.26 | 0.3591 |
|
| |||||
| Net Profit Margin | 0.17 | 0.1606 |
|
| |||||
| Operating Profit Margin | 0.1 | 0.1903 |
|
| |||||
| Pretax Profit Margin | 0.21 | 0.1955 |
|
| |||||
| Return On Assets | 0.13 | 0.12 |
|
| |||||
| Return On Equity | 0.096 | 0.17 |
|
|
For West Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of West Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well West Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between West Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of West Pharmaceutical over time as well as its relative position and ranking within its peers.
West Pharmaceutical Earnings per Share Projection vs Actual
The next projected EPS of West Pharmaceutical is estimated to be 1.6778 with future projections ranging from a low of 1.65 to a high of 1.693. West Pharmaceutical's most recent 12-month trailing earnings per share (EPS TTM) is at 6.79. Please be aware that the consensus of earnings estimates for West Pharmaceutical Services is based on EPS before non-recurring items and includes expenses related to employee stock options.West Pharmaceutical Earnings Estimation Breakdown
The calculation of West Pharmaceutical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of West Pharmaceutical is estimated to be 1.6778 with the future projection ranging from a low of 1.65 to a high of 1.693. Please be aware that this consensus of annual earnings estimates for West Pharmaceutical Services is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.65 Lowest | Expected EPS | 1.69 Highest |
West Pharmaceutical Earnings Projection Consensus
Suppose the current estimates of West Pharmaceutical's value are higher than the current market price of the West Pharmaceutical stock. In this case, investors may conclude that West Pharmaceutical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and West Pharmaceutical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 16 | 87.22% | 2.04 | 1.6778 | 6.79 |
West Pharmaceutical Ownership Allocation
West Pharmaceutical Services retains a total of 72.04 Million outstanding shares. The majority of West Pharmaceutical outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in West Pharmaceutical to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in West Pharmaceutical Services. Please pay attention to any change in the institutional holdings of West Pharmaceutical as this could imply that something significant has changed or is about to change at the company. Please note that on March 7, 2025, Representative Jared Moskowitz of US Congress acquired under $15k worth of West Pharmaceutical's common stock.West Pharmaceutical Profitability Analysis
The company reported the last year's revenue of 3.07 B. Total Income to common stockholders was 493.7 M with profit before taxes, overhead, and interest of 1.1 B.West Pharmaceutical Past Distributions to stockholders
About West Pharmaceutical Valuation
The stock valuation mechanism determines West Pharmaceutical's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of West Pharmaceutical based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of West Pharmaceutical. We calculate exposure to West Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of West Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.1 B | 1.2 B | |
| Pretax Profit Margin | 0.20 | 0.21 | |
| Operating Profit Margin | 0.19 | 0.10 | |
| Net Profit Margin | 0.16 | 0.17 | |
| Gross Profit Margin | 0.36 | 0.26 |
West Pharmaceutical Quarterly Retained Earnings |
|
A single share of West Pharmaceutical represents a small ownership stake in the entity. As a stockholder of West, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
West Pharmaceutical Dividends Analysis For Valuation
Dividend Paid And Capex Coverage Ratio is likely to gain to 2.28 in 2026, despite the fact that Dividends Paid is likely to grow to (58.1 M). . At this time, West Pharmaceutical's Retained Earnings are comparatively stable compared to the past year. Retained Earnings Total Equity is likely to gain to about 3.6 B in 2026, whereas Price Earnings Ratio is likely to drop 23.78 in 2026.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -61.2 M | -58.1 M | |
| Dividend Payout Ratio | 0.12 | 0.12 | |
| Dividend Paid And Capex Coverage Ratio | 2.17 | 2.28 |
There are various types of dividends West Pharmaceutical can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of West shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from West Pharmaceutical Services directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When West pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of West Pharmaceutical by the value of the dividends paid out.
West Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as West Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 72.7 M | |
| Quarterly Earnings Growth Y O Y | 0.021 | |
| Forward Price Earnings | 33.3333 |
West Pharmaceutical Current Valuation Indicators
West Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final West Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as West Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use West Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes West Pharmaceutical's worth.Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.